Cargando…

PEACE V – Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial

BACKGROUND: Pelvic nodal recurrences are being increasingly diagnosed with the introduction of new molecular imaging techniques, like choline and PSMA PET-CT, in the restaging of recurrent prostate cancer (PCa). At this moment, there are no specific treatment recommendations for patients with limite...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Bruycker, A., Spiessens, A., Dirix, P., Koutsouvelis, N., Semac, I., Liefhooghe, N., Gomez-Iturriaga, A., Everaerts, W., Otte, F., Papachristofilou, A., Scorsetti, M., Shelan, M., Siva, S., Ameye, F., Guckenberger, M., Heikkilä, R., Putora, P. M., Zapatero, A., Conde-Moreno, A., Couñago, F., Vanhoutte, F., Goetghebeur, E., Reynders, D., Zilli, T., Ost, P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216526/ https://www.ncbi.nlm.nih.gov/pubmed/32398040 http://dx.doi.org/10.1186/s12885-020-06911-4

Ejemplares similares

Elective Nodal Irradiation for Oligorecurrent Nodal Prostate Cancer: Interobserver Variability in the PEACE V-STORM Randomized Phase 2 Trial
por: Lorton, Orane, et al.
Publicado: (2023)

Node Oligorecurrence in Prostate Cancer: A Challenge
por: Zapatero, Almudena, et al.
Publicado: (2023)

A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer
por: De Bleser, Elise, et al.
Publicado: (2020)

Metastasis-directed therapy: a new standard for oligorecurrent prostate cancer?
por: Zilli, Thomas, et al.
Publicado: (2018)

Stereotactic body radiotherapy to defer systemic therapy in patients with oligorecurrent disease
por: Willmann, Jonas, et al.
Publicado: (2022)

SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
por: Rans, Kato, et al.
Publicado: (2022)

Radiotherapy in nodal oligorecurrent prostate cancer
por: Pinkawa, Michael, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy
por: Schröder, Christina, et al.
Publicado: (2019)

Correction to: ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial
por: Zilli, Thomas, et al.
Publicado: (2018)

Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer
por: Stefan A. Koerber, et al.
Publicado: (2020)

Defining the role of high-dose radiation in oligometastatic & oligorecurrent cervical cancer
por: Mangaj, Akshay, et al.
Publicado: (2021)

Radiotherapy in Oligometastatic, Oligorecurrent and Oligoprogressive Prostate Cancer: A Mini-Review
por: Yaney, Alexander, et al.
Publicado: (2022)

Lung Radiofrequency Ablation: Potential as a Therapy to Oligometastasis and Oligorecurrence
por: Hiraki, Takao, et al.
Publicado: (2012)

Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases
por: Berkovic, Patrick, et al.
Publicado: (2020)

Repeated Multimodality Ablative Therapies for Oligorecurrent Pulmonary Metastatic Disease
por: Macagno, Alban, et al.
Publicado: (2022)

Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes
por: Wang, Huan-Huan, et al.
Publicado: (2016)

Proton Beam Therapy in the Oligometastatic/Oligorecurrent Setting: Is There a Role? A Literature Review
por: Gaito, Simona, et al.
Publicado: (2023)

Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy
por: Henkenberens, Christoph, et al.
Publicado: (2020)

Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [(68)Ga]PSMA-PET-guided metastasis-directed therapy
por: Vogel, Marco M. E., et al.
Publicado: (2020)

Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance
por: Triggiani, Luca, et al.
Publicado: (2021)

Pulmonary large cell neuroendocrine carcinoma with adrenal oligorecurrence successfully treated by adrenalectomy
por: Sato, Hiroki, et al.
Publicado: (2020)

Objective consensus from decision trees
por: Putora, Paul Martin, et al.
Publicado: (2014)

MRI detected extaprostatic extension (EPE) in prostate cancer: Do all T3a patients have the same outcomes?
por: Gomez-Iturriaga, A., et al.
Publicado: (2020)

Combining (68)Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study
por: Kirste, Simon, et al.
Publicado: (2021)

Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer()
por: Levy, Antonin, et al.
Publicado: (2023)

Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy
por: Devos, Gaëtan, et al.
Publicado: (2020)

Radioablation +/− hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159)
por: Marvaso, Giulia, et al.
Publicado: (2019)

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer
por: Kissel, Manon, et al.
Publicado: (2019)

Proton Beam Therapy With Space-Making Surgery (Omental Plombage) for Oligorecurrent Liver Metastasis of Esophageal Adenocarcinoma
por: Ishikawa, Yojiro, et al.
Publicado: (2022)

PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment
por: Bianchi, Lorenzo, et al.
Publicado: (2023)

Are all prostate cancer patients "fit" for salvage radiotherapy?
por: González-San Segundo, Carmen, et al.
Publicado: (2020)

Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study
por: Triggiani, Luca, et al.
Publicado: (2017)

Elective nodal radiotherapy with a gapless radiation field junction for oligorecurrent prostate cancer after previous radiotherapy
por: Li, Minglun, et al.
Publicado: (2022)

Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice
por: Panje, Cedric, et al.
Publicado: (2019)

An 87-year-old patient with repeated oligorecurrences over six years whose disease were treated with radiotherapy alone
por: Yun, Hyong Geun
Publicado: (2014)

Comment on ‘Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study’
por: Bravo, Isabel
Publicado: (2018)

Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review
por: Cozzi, Salvatore, et al.
Publicado: (2022)

ESTRO ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer
por: Dal Pra, Alan, et al.
Publicado: (2023)

Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease
por: Henriquez, Ivan, et al.
Publicado: (2021)

Extreme Hypofractionation with SBRT in Localized Prostate Cancer
por: Gómez-Aparicio, Maria Antonia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mm65qjpvmcg25pe2d33di7c50q